Over the past 20–30 years there has been a dramatic increase in the number of people living with immunosuppression. Cancer chemotherapy and the treatment of haematological disease transiently put people at risk, while the immunosuppression required for solid organ transplants and for immunemediated diseases, such as systemic lupus erythematosus, is more prolonged. In addition to these iatrogeni...